Compare FRST & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | IMMP |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 264.9M |
| IPO Year | 2006 | N/A |
| Metric | FRST | IMMP |
|---|---|---|
| Price | $13.40 | $2.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.1K | ★ 1.7M |
| Earning Date | 01-27-2026 | 02-22-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $138,816,000.00 | $3,306,742.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $35.05 | N/A |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | ★ 33.08 | 31.28 |
| 52 Week Low | $7.59 | $1.32 |
| 52 Week High | $13.46 | $3.53 |
| Indicator | FRST | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 80.14 | 66.08 |
| Support Level | $11.01 | $1.67 |
| Resistance Level | $12.47 | $2.68 |
| Average True Range (ATR) | 0.34 | 0.26 |
| MACD | 0.21 | 0.08 |
| Stochastic Oscillator | 95.44 | 41.94 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.